HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: At present, a variety of HDAC inhibitors are under clinical investigation, while two HDAC inhibitors, SAHA (vorinostat) and FK228 (romidepsin), were already approved for the treatment of cutaneous T-cell lymphomas [14].